Try one of the below options to narrow down your search.
 |
Documents may be browsed by date, eg; Today, May, 2013.
Past years can be browsed too, eg; 2012, 2011, 2010, 2009 ...
Documents can be searched within a period by browsing to the date and then using the search form; or by direct links, eg; Media releases from 2013
Document tags (shown below the document date, eg; Schedule, SAForms, consultation ...) have highest priority when search results are ranked, followed by title, abstract and full text of document.
Parentheses and the keywords and, or and not have special meaning in search terms. And is implicit and can be omitted; or must be specified.
Remember to group or statements with parentheses if they are beside and statements.
Search examples
- consultation
- Search for consultations
- media and not antibiotics
- Search for media related documents that don't mention antibiotics.
- (media or consultation) and vaccines
- Search for media releases and consultation documents mentioning vaccinations.
Search term: herceptin
The term herceptin matches (either partially, or fully) a brand or chemical name in Pharmaceutical Schedule.
The term herceptin matches (either partially, or fully) a brand or chemical name in Application Tracker.
PHARMAC documents that matched your search:
Applications received since 1 December 2008
(12 pages, 113 KB)
2012/05/09
“Herceptin) A556583 - qA26314 Indication Gaucher’s disease AL amyloidosis HER 2 positive metastatic breast cancer”
Applications received for new investments since 1 November 2008 Details of Funding Applications received are published on PHARMAC’s website, in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008. Applications Received…
2012-04 Clinicians Newsletter
(4 pages, 219 KB)
2012/03/29
“Herceptin) for the first line treatment of patients with HER 2 positive metastatic breast cancer”
Pharmaceutical Management Agency Clinicians’ “Make life easier, always think generically” Newsletter March/April 2012 Named Patient Pharmaceutical Assessment (NPPA) From 1 March 2012, PHARMAC’s Exceptional Circumstances (EC) schemes were replaced with Named Patient Pharmaceutical Assessment (NPPA). The changes are aimed at…
Pharmaceutical Schedule - effective 1 April 2012
(242 pages, 1459 KB)
2012/03/28
“Herceptin Inj 440 mg vial .............................................................................3,875.00 1 Herceptin Inj 1 mg for ECP .................................................................................9.36 1 mg Baxter”
Pharmaceutical Management Agency April 2012 New Zealand Pharmaceutical Schedule April 2012 Volume 19 Number 1 Editors: Kaye Wilson, Rebecca Bloor & Donna Jennings email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street…
Schedule Update - effective 1 April 2012
(59 pages, 747 KB)
2012/03/16
“Herceptin ✔ Herceptin ✔ Baxter TRASTUZUMAB – PCT only – Specialist – Special Authority see SA1192 1163 Inj 150 mg vial”
Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 April 2012 Cumulative for January, February, March and April 2012 Section H for April 2012 Contents Summary of PHARMAC decisions effective 1 April 2012 …. 3 Ethinyloestradiol with levonorgestrel ……
2012-04 Schedule Dispatch
(2 pages, 86 KB)
2012/03/16
“Herceptin) – amended Special Authority Tiotropium bromide (Spiriva) – amended Special Authority A491393 - qA22814 Decreased subsidy Chemical”
16 March 2012 April 2012 Pharmaceutical Schedule Dispatch This document is provided to pharmacists as an early notification of the changes to be announced in the April 2012 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50)…
Two new cancer treatments funded: lapatinib and pazopanib
(2 pages, 63 KB)
2012/03/05
“Herceptin) for advanced HER 2 positive breast cancer patients and sunitinib (Sutent) for advanced kidney”
2 March 2012 Media release Two new targeted cancer drugs funded in agreement PHARMAC is funding two new targeted cancer medicines following an agreement with GlaxoSmithKline. From 1 April 2012 PHARMAC will begin funding lapatinib (Tykerb) and pazopanib (Votrient). These…
Approval of proposal for pazopanib, lapatinib and trastuzumab; Contact: Notifications; Posted: 2012-03-01
(7 pages, 165 KB)
2012/03/01
“Herceptin): The Special Authority criteria applying to all presentations of trastuzumab (Herceptin) in Section B of the Pharmaceutical”
1 March 2012 Approval of proposal to fund pazopanib, lapatinib and amend the Special Authority criteria applying to trastuzumab PHARMAC is pleased to announce approval of the proposal to fund pazopanib (Votrient) and lapatinib (Tykerb) and amend the Special Authority…
Section H - effective 1 March 2012
(82 pages, 999 KB)
2012/02/27
“Herceptin Herceptin Vesanoid Oracort Aristocort Aristocort Kenacort-A Kenacort-A40 7.5 ml 100 500 ml 50 15 ml 15 ml 5 1 1 100 100 30 1 Kenacomb”
Pharmaceutical Management Agency Section H for Hospital Pharmaceuticals Effective 1 March 2012 New Zealand Pharmaceutical Schedule Hospital Pharmaceuticals March 2012 Editors Rebecca Bloor & Donna Jennings email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9,…
Schedule Update - effective 1 March 2012
(62 pages, 895 KB)
2012/02/16
“Herceptin) and inj 1 mg for ECP (Baxter) – amend Special Authority criteria to include patients”
Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 March 2012 Cumulative for January, February and March 2012 Section H cumulative for December 2011, January, February and March 2012 Contents Summary of PHARMAC decisions effective 1 March 2012 …..…
Proposal to fund lapatinib and pazopanib and amend funding criteria for trastuzumab; Closing Date: Closed; Contact: Jackie Evans
(7 pages, 154 KB)
2012/01/26
“Herceptin): The Special Authority criteria applying to all presentations of trastuzumab (Herceptin) in Section B of the Pharmaceutical”
26 January 2012 Proposal to fund lapatinib and pazopanib and amend funding criteria for trastuzumab PHARMAC is seeking feedback on a proposal to: Fund lapatinib (Tykerb) as an alternative to trastuzumab (Herceptin) for the first line treatment of patients…
Page updated on 26 May 2013
